Axcan & Eurand change to Aptalis
Friday, May 6, 2011
Axcan Intermediate Holdings has changed its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies focused on gastrointestinal diseases: Axcan and Eurand.
Aptalis currently markets several products around the world and has several compounds in various stages of development targeting unmet medical needs. The pipeline includes a recent acquisition, Aeroquin from Mpex Pharmaceuticals, currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.